Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_assertion type Assertion NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_head.
- NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_assertion description "[(i) Like normal kidney, virtually all primary human renal cell carcinomas express MHC class I antigens and retain this phenotype even during tumor progression and metastasis; (ii) class II expression on normal and RCC cells appears more limited but occurs frequently in both primary and metastatic lesions; and (iii) in most continuous RCC cell lines expression of MHC class I and II can effectively be stimulated by IFN-gamma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_provenance.
- NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_assertion evidence source_evidence_literature NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_provenance.
- NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_assertion SIO_000772 7490887 NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_provenance.
- NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_assertion wasDerivedFrom befree-20150227 NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_provenance.
- NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_assertion wasGeneratedBy ECO_0000203 NP479816.RADiorECA_bHDGSqYLc51zAcDSRI9SBV4oG18Lz1zE_gg130_provenance.